Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Fast Track Articles
  5. Fast Track Article
image of Prognostic Role of Global DNA Methylation in Renal Cancer Reveals Decitabine Treatment Benefit

Abstract

Background

Renal cancer presents a significant global health challenge due to its rising incidence and mortality rates. Often undetected in early stages, it complicates diagnosis and treatment. Current therapies face resistance and limited effectiveness, especially in advanced stages. The diverse subtypes of renal cancer highlight the need for new biomarkers and risk assessment tools for targeted treatments.

Objective

This study aims to assess the prognostic significance of global DNA methylation (GM) levels in renal cancer, identify new biomarkers, and evaluate the therapeutic potential of the DNA methyltransferase inhibitor decitabine.

Method

Data on RNA sequencing, gene mutations, DNA methylation, and clinical outcomes were collected from TCGA and GEO databases. We calculated global DNA methylation scores (GMS) and categorized patients into high, intermediate, and low GMS groups. Survival analysis and genomic analyses were conducted to explore the relationships between GMS, clinical outcomes, and tumor characteristics.

Results

Higher GMS was identified as an independent prognostic factor associated with worse outcomes in renal cancer. Patients with elevated GMS showed increased mutations, copy number variations, and a more aggressive tumor phenotype. Treatment with decitabine was observed to reduce tumor hypermethylation and downregulate cell cycle pathway activity, indicating potential therapeutic benefits.

Conclusion

Global DNA methylation plays a significant role in renal cancer prognosis. GMS may serve as valuable biomarkers for prognosis and personalized treatment strategies. Decitabine shows potential efficacy for high GMS patients, particularly through its impact on cell cycle regulation, underscoring the importance of personalized approaches in cancer treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673342146250217105350
2025-03-12
2025-04-10

  • From This Site

    /content/journals/cmc/10.2174/0109298673342146250217105350
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018 68 6 394 424 10.3322/caac.21492 30207593
    [Google Scholar]
  3. Escudier B. Porta C. Schmidinger M. Rioux-Leclercq N. Bex A. Khoo V. Grünwald V. Gillessen S. Horwich A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019 30 5 706 720 10.1093/annonc/mdz056 30788497
    [Google Scholar]
  4. Menko F.H. Maher E.R. Schmidt L.S. Middelton L.A. Aittomäki K. Tomlinson I. Richard S. Linehan W.M. Hereditary leiomyomatosis and renal cell cancer (HLRCC): Renal cancer risk, surveillance and treatment. Fam. Cancer 2014 13 4 637 644 10.1007/s10689‑014‑9735‑2 25012257
    [Google Scholar]
  5. Larroquette M. Peyraud F. Domblides C. Lefort F. Bernhard J.C. Ravaud A. Gross-Goupil M. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives. Cancer Treat. Rev. 2021 97 102207 10.1016/j.ctrv.2021.102207 33906023
    [Google Scholar]
  6. Song X. Tian Y. Li H. Liu B. Zhang A. Hong Y. Research progress on advanced renal cell carcinoma. J. Int. Med. Res. 2020 48 6 0300060520924265 10.1177/0300060520924265 32529862
    [Google Scholar]
  7. Khan Y. Slattery T.D. Pickering L.M. Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. Cancers (Basel) 2020 12 12 3750 10.3390/cancers12123750 33322163
    [Google Scholar]
  8. Chen W. Zhuang J. Wang P.P. Jiang J. Lin C. Zeng P. Liang Y. Zhang X. Dai Y. Diao H. DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups. Cancer Cell Int. 2019 19 1 185 10.1186/s12935‑019‑0900‑4 31346320
    [Google Scholar]
  9. Hsieh J.J. Le V. Cao D. Cheng E.H. Creighton C.J. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J. Pathol. 2018 244 5 525 537 10.1002/path.5022 29266437
    [Google Scholar]
  10. Haake S.M. Rathmell W.K. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Cancer 2017 123 2 200 209 10.1002/cncr.30314 27861752
    [Google Scholar]
  11. Kim M. Joo J.W. Lee S.J. Cho Y.A. Park C.K. Cho N.H. Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes. Cancers (Basel) 2020 12 3 602 10.3390/cancers12030602 32150988
    [Google Scholar]
  12. Crumley S.M. Divatia M. Truong L. Shen S. Ayala A.G. Ro J.Y. Renal cell carcinoma: Evolving and emerging subtypes. World J. Clin. Cases 2013 1 9 262 275 10.12998/wjcc.v1.i9.262 24364021
    [Google Scholar]
  13. Low G. Huang G. Fu W. Moloo Z. Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J. Radiol. 2016 8 5 484 500 10.4329/wjr.v8.i5.484 27247714
    [Google Scholar]
  14. Gupta S. Shamsher Singh K. Biomarkers in renal cell carcinoma and their targeted therapies: a review. Explor. Target. Antitumor Ther. 2023 4 5 941 961 10.37349/etat.2023.00175 37970211
    [Google Scholar]
  15. Issa J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004 4 12 988 993 10.1038/nrc1507 15573120
    [Google Scholar]
  16. Issa J.P. CpG-island methylation in aging and cancer. Curr. Top. Microbiol. Immunol. 2000 249 101 118 10.1007/978‑3‑642‑59696‑4_7 10802941
    [Google Scholar]
  17. Zheng Y. Huang G. Silva T.C. Yang Q. Jiang Y.Y. Koeffler H.P. Lin D.C. Berman B.P. A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes. Nat. Commun. 2021 12 1 2485 10.1038/s41467‑021‑22720‑0 33931649
    [Google Scholar]
  18. Peters I. Eggers H. Atschekzei F. Hennenlotter J. Waalkes S. Tränkenschuh W. Großhennig A. Merseburger A.S. Stenzl A. Kuczyk M.A. Serth J. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int. 2012 110 2b E144 E152 10.1111/j.1464‑410X.2011.10862.x 22289415
    [Google Scholar]
  19. Kawai Y. Sakano S. Suehiro Y. Okada T. Korenaga Y. Hara T. Naito K. Matsuyama H. Hinoda Y. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann. Oncol. 2010 21 8 1612 1617 10.1093/annonc/mdp577 20038516
    [Google Scholar]
  20. Fisel P. Kruck S. Winter S. Bedke J. Hennenlotter J. Nies A.T. Scharpf M. Fend F. Stenzl A. Schwab M. Schaeffeler E. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Clin. Cancer Res. 2013 19 18 5170 5181 10.1158/1078‑0432.CCR‑13‑1180 23881922
    [Google Scholar]
  21. Chen F. Zhang Y. Şenbabaoğlu Y. Ciriello G. Yang L. Reznik E. Shuch B. Micevic G. De Velasco G. Shinbrot E. Noble M.S. Lu Y. Covington K.R. Xi L. Drummond J.A. Muzny D. Kang H. Lee J. Tamboli P. Reuter V. Shelley C.S. Kaipparettu B.A. Bottaro D.P. Godwin A.K. Gibbs R.A. Getz G. Kucherlapati R. Park P.J. Sander C. Henske E.P. Zhou J.H. Kwiatkowski D.J. Ho T.H. Choueiri T.K. Hsieh J.J. Akbani R. Mills G.B. Hakimi A.A. Wheeler D.A. Creighton C.J. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016 14 10 2476 2489 10.1016/j.celrep.2016.02.024 26947078
    [Google Scholar]
  22. Linehan W.M. Spellman P.T. Ricketts C.J. Creighton C.J. Fei S.S. Davis C. Wheeler D.A. Murray B.A. Schmidt L. Vocke C.D. Peto M. Al Mamun A.A. Shinbrot E. Sethi A. Brooks S. Rathmell W.K. Brooks A.N. Hoadley K.A. Robertson A.G. Brooks D. Bowlby R. Sadeghi S. Shen H. Weisenberger D.J. Bootwalla M. Baylin S.B. Laird P.W. Cherniack A.D. Saksena G. Haake S. Li J. Liang H. Lu Y. Mills G.B. Akbani R. Leiserson M.D. Raphael B.J. Anur P. Bottaro D. Albiges L. Barnabas N. Choueiri T.K. Czerniak B. Godwin A.K. Hakimi A.A. Ho T.H. Hsieh J. Ittmann M. Kim W.Y. Krishnan B. Merino M.J. Mills Shaw K.R. Reuter V.E. Reznik E. Shelley C.S. Shuch B. Signoretti S. Srinivasan R. Tamboli P. Thomas G. Tickoo S. Burnett K. Crain D. Gardner J. Lau K. Mallery D. Morris S. Paulauskis J.D. Penny R.J. Shelton C. Shelton W.T. Sherman M. Thompson E. Yena P. Avedon M.T. Bowen J. Gastier-Foster J.M. Gerken M. Leraas K.M. Lichtenberg T.M. Ramirez N.C. Santos T. Wise L. Zmuda E. Demchok J.A. Felau I. Hutter C.M. Sheth M. Sofia H.J. Tarnuzzer R. Wang Z. Yang L. Zenklusen J.C. Zhang J. Ayala B. Baboud J. Chudamani S. Liu J. Lolla L. Naresh R. Pihl T. Sun Q. Wan Y. Wu Y. Ally A. Balasundaram M. Balu S. Beroukhim R. Bodenheimer T. Buhay C. Butterfield Y.S. Carlsen R. Carter S.L. Chao H. Chuah E. Clarke A. Covington K.R. Dahdouli M. Dewal N. Dhalla N. Doddapaneni H.V. Drummond J.A. Gabriel S.B. Gibbs R.A. Guin R. Hale W. Hawes A. Hayes D.N. Holt R.A. Hoyle A.P. Jefferys S.R. Jones S.J. Jones C.D. Kalra D. Kovar C. Lewis L. Li J. Ma Y. Marra M.A. Mayo M. Meng S. Meyerson M. Mieczkowski P.A. Moore R.A. Morton D. Mose L.E. Mungall A.J. Muzny D. Parker J.S. Perou C.M. Roach J. Schein J.E. Schumacher S.E. Shi Y. Simons J.V. Sipahimalani P. Skelly T. Soloway M.G. Sougnez C. Tam A. Tan D. Thiessen N. Veluvolu U. Wang M. Wilkerson M.D. Wong T. Wu J. Xi L. Zhou J. Bedford J. Chen F. Fu Y. Gerstein M. Haussler D. Kasaian K. Lai P. Ling S. Radenbaugh A. Van Den Berg D. Weinstein J.N. Zhu J. Albert M. Alexopoulou I. Andersen J.J. Auman J.T. Bartlett J. Bastacky S. Bergsten J. Blute M.L. Boice L. Bollag R.J. Boyd J. Castle E. Chen Y.B. Cheville J.C. Curley E. Davies B. DeVolk A. Dhir R. Dike L. Eckman J. Engel J. Harr J. Hrebinko R. Huang M. Huelsenbeck-Dill L. Iacocca M. Jacobs B. Lobis M. Maranchie J.K. McMeekin S. Myers J. Nelson J. Parfitt J. Parwani A. Petrelli N. Rabeno B. Roy S. Salner A.L. Slaton J. Stanton M. Thompson R.H. Thorne L. Tucker K. Weinberger P.M. Winemiller C. Zach L.A. Zuna R. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 2016 374 2 135 145 10.1056/NEJMoa1505917 26536169
    [Google Scholar]
  23. Barata P.C. Rini B.I. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J. Clin. 2017 67 6 507 524 10.3322/caac.21411 28961310
    [Google Scholar]
  24. Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions. Clin. Cancer Res. 2007 13 4 1098 1106 10.1158/1078‑0432.CCR‑06‑1989 17317817
    [Google Scholar]
  25. Voss M.H. Motzer R.J. Adjuvant immunotherapy for kidney cancer — a new strategy with new challenges. N. Engl. J. Med. 2024 390 15 1432 1433 10.1056/NEJMe2402364 38631007
    [Google Scholar]
  26. Wasserman M. Sobel D. Pareek G. Choice of surgical options in kidney cancer and surgical complications. Semin. Nephrol. 2020 40 1 42 48 10.1016/j.semnephrol.2019.12.005 32130965
    [Google Scholar]
  27. Launay-Vacher V. Aapro M. De Castro G. Jr Cohen E. Deray G. Dooley M. Humphreys B. Lichtman S. Rey J. Scotté F. Wildiers H. Sprangers B. Renal effects of molecular targeted therapies in oncology: A review by the Cancer and the Kidney International Network (C-KIN). Ann. Oncol. 2015 26 8 1677 1684 10.1093/annonc/mdv136 25735315
    [Google Scholar]
  28. Munteanu R. Tomuleasa C. Iuga C.A. Gulei D. Ciuleanu T.E. Exploring therapeutic avenues in lung cancer: The epigenetic perspective. Cancers (Basel) 2023 15 22 5394 10.3390/cancers15225394 38001653
    [Google Scholar]
  29. Pappalardi M.B. Keenan K. Cockerill M. Kellner W.A. Stowell A. Sherk C. Wong K. Pathuri S. Briand J. Steidel M. Chapman P. Groy A. Wiseman A.K. McHugh C.F. Campobasso N. Graves A.P. Fairweather E. Werner T. Raoof A. Butlin R.J. Rueda L. Horton J.R. Fosbenner D.T. Zhang C. Handler J.L. Muliaditan M. Mebrahtu M. Jaworski J.P. McNulty D.E. Burt C. Eberl H.C. Taylor A.N. Ho T. Merrihew S. Foley S.W. Rutkowska A. Li M. Romeril S.P. Goldberg K. Zhang X. Kershaw C.S. Bantscheff M. Jurewicz A.J. Minthorn E. Grandi P. Patel M. Benowitz A.B. Mohammad H.P. Gilmartin A.G. Prinjha R.K. Ogilvie D. Carpenter C. Heerding D. Baylin S.B. Jones P.A. Cheng X. King B.W. Luengo J.I. Jordan A.M. Waddell I. Kruger R.G. McCabe M.T. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat. Cancer 2021 2 10 1002 1017 10.1038/s43018‑021‑00249‑x 34790902
    [Google Scholar]
  30. Yamada Y. Venkadakrishnan V.B. Mizuno K. Bakht M. Ku S.Y. Garcia M.M. Beltran H. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci. Transl. Med. 2023 15 722 eadf6732 10.1126/scitranslmed.adf6732 37967200
    [Google Scholar]
  31. Achinger-Kawecka J. Stirzaker C. Portman N. Campbell E. Chia K.M. Du Q. Laven-Law G. Nair S.S. Yong A. Wilkinson A. Clifton S. Milioli H.H. Alexandrou S. Caldon C.E. Song J. Khoury A. Meyer B. Chen W. Pidsley R. Qu W. Gee J.M.W. Schmitt A. Wong E.S. Hickey T.E. Lim E. Clark S.J. The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer. Nat. Struct. Mol. Biol. 2024 31 3 498 512 10.1038/s41594‑023‑01181‑7 38182927
    [Google Scholar]
  32. Hoang N.M. Liu Y. Bates P.D. Heaton A.R. Lopez A.F. Liu P. Zhu F. Chen R. Kondapelli A. Zhang X. Selberg P.E. Ngo V.N. Skala M.C. Capitini C.M. Rui L. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. Cell Rep. Med. 2024 5 4 101484 10.1016/j.xcrm.2024.101484 38554704
    [Google Scholar]
  33. Li H.T. Jang H.J. Rohena-Rivera K. Liu M. Gujar H. Kulchycki J. Zhao S. Billet S. Zhou X. Weisenberger D.J. Gill I. Jones P.A. Bhowmick N.A. Liang G. RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer. Cell Rep. 2023 42 1 112016 10.1016/j.celrep.2023.112016 36662621
    [Google Scholar]
  34. de Cubas A.A. Dunker W. Zaninovich A. Hongo R.A. Bhatia A. Panda A. Beckermann K.E. Bhanot G. Ganesan S. Karijolich J. Rathmell W.K. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. JCI Insight 2020 5 11 e137569 10.1172/jci.insight.137569 32493845
    [Google Scholar]
  35. Wang Z. Zhang T. Wu W. Wu L. Li J. Huang B. Liang Y. Li Y. Li P. Li K. Wang W. Guo R. Wang Q. Detection and localization of solid tumors utilizing the cancer-type-specific mutational signatures. Front. Bioeng. Biotechnol. 2022 10 883791 10.3389/fbioe.2022.883791 35547159
    [Google Scholar]
  36. Mermel C.H. Schumacher S.E. Hill B. Meyerson M.L. Beroukhim R. Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011 12 4 R41 10.1186/gb‑2011‑12‑4‑r41 21527027
    [Google Scholar]
  37. Chen E.Y. Tan C.M. Kou Y. Duan Q. Wang Z. Meirelles G.V. Clark N.R. Ma’ayan A. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 2013 14 1 128 10.1186/1471‑2105‑14‑128 23586463
    [Google Scholar]
  38. Xu S. Hu E. Cai Y. Xie Z. Luo X. Zhan L. Tang W. Wang Q. Liu B. Wang R. Xie W. Wu T. Xie L. Yu G. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 2024 19 11 3292 3320 10.1038/s41596‑024‑01020‑z 39019974
    [Google Scholar]
  39. Malta T.M. Sokolov A. Gentles A.J. Burzykowski T. Poisson L. Weinstein J.N. Kamińska B. Huelsken J. Omberg L. Gevaert O. Colaprico A. Czerwińska P. Mazurek S. Mishra L. Heyn H. Krasnitz A. Godwin A.K. Lazar A.J. Stuart J.M. Hoadley K.A. Laird P.W. Noushmehr H. Wiznerowicz M. Caesar-Johnson S.J. Demchok J.A. Felau I. Kasapi M. Ferguson M.L. Hutter C.M. Sofia H.J. Tarnuzzer R. Wang Z. Yang L. Zenklusen J.C. Zhang J.J. Chudamani S. Liu J. Lolla L. Naresh R. Pihl T. Sun Q. Wan Y. Wu Y. Cho J. DeFreitas T. Frazer S. Gehlenborg N. Getz G. Heiman D.I. Kim J. Lawrence M.S. Lin P. Meier S. Noble M.S. Saksena G. Voet D. Zhang H. Bernard B. Chambwe N. Dhankani V. Knijnenburg T. Kramer R. Leinonen K. Liu Y. Miller M. Reynolds S. Shmulevich I. Thorsson V. Zhang W. Akbani R. Broom B.M. Hegde A.M. Ju Z. Kanchi R.S. Korkut A. Li J. Liang H. Ling S. Liu W. Lu Y. Mills G.B. Ng K-S. Rao A. Ryan M. Wang J. Weinstein J.N. Zhang J. Abeshouse A. Armenia J. Chakravarty D. Chatila W.K. de Bruijn I. Gao J. Gross B.E. Heins Z.J. Kundra R. La K. Ladanyi M. Luna A. Nissan M.G. Ochoa A. Phillips S.M. Reznik E. Sanchez-Vega F. Sander C. Schultz N. Sheridan R. Sumer S.O. Sun Y. Taylor B.S. Wang J. Zhang H. Anur P. Peto M. Spellman P. Benz C. Stuart J.M. Wong C.K. Yau C. Hayes D.N. Parker J.S. Wilkerson M.D. Ally A. Balasundaram M. Bowlby R. Brooks D. Carlsen R. Chuah E. Dhalla N. Holt R. Jones S.J.M. Kasaian K. Lee D. Ma Y. Marra M.A. Mayo M. Moore R.A. Mungall A.J. Mungall K. Robertson A.G. Sadeghi S. Schein J.E. Sipahimalani P. Tam A. Thiessen N. Tse K. Wong T. Berger A.C. Beroukhim R. Cherniack A.D. Cibulskis C. Gabriel S.B. Gao G.F. Ha G. Meyerson M. Schumacher S.E. Shih J. Kucherlapati M.H. Kucherlapati R.S. Baylin S. Cope L. Danilova L. Bootwalla M.S. Lai P.H. Maglinte D.T. Van Den Berg D.J. Weisenberger D.J. Auman J.T. Balu S. Bodenheimer T. Fan C. Hoadley K.A. Hoyle A.P. Jefferys S.R. Jones C.D. Meng S. Mieczkowski P.A. Mose L.E. Perou A.H. Perou C.M. Roach J. Shi Y. Simons J.V. Skelly T. Soloway M.G. Tan D. Veluvolu U. Fan H. Hinoue T. Laird P.W. Shen H. Zhou W. Bellair M. Chang K. Covington K. Creighton C.J. Dinh H. Doddapaneni H.V. Donehower L.A. Drummond J. Gibbs R.A. Glenn R. Hale W. Han Y. Hu J. Korchina V. Lee S. Lewis L. Li W. Liu X. Morgan M. Morton D. Muzny D. Santibanez J. Sheth M. Shinbrot E. Wang L. Wang M. Wheeler D.A. Xi L. Zhao F. Hess J. Appelbaum E.L. Bailey M. Cordes M.G. Ding L. Fronick C.C. Fulton L.A. Fulton R.S. Kandoth C. Mardis E.R. McLellan M.D. Miller C.A. Schmidt H.K. Wilson R.K. Crain D. Curley E. Gardner J. Lau K. Mallery D. Morris S. Paulauskis J. Penny R. Shelton C. Shelton T. Sherman M. Thompson E. Yena P. Bowen J. Gastier-Foster J.M. Gerken M. Leraas K.M. Lichtenberg T.M. Ramirez N.C. Wise L. Zmuda E. Corcoran N. Costello T. Hovens C. Carvalho A.L. de Carvalho A.C. Fregnani J.H. Longatto-Filho A. Reis R.M. Scapulatempo-Neto C. Silveira H.C.S. Vidal D.O. Burnette A. Eschbacher J. Hermes B. Noss A. Singh R. Anderson M.L. Castro P.D. Ittmann M. Huntsman D. Kohl B. Le X. Thorp R. Andry C. Duffy E.R. Lyadov V. Paklina O. Setdikova G. Shabunin A. Tavobilov M. McPherson C. Warnick R. Berkowitz R. Cramer D. Feltmate C. Horowitz N. Kibel A. Muto M. Raut C.P. Malykh A. Barnholtz-Sloan J.S. Barrett W. Devine K. Fulop J. Ostrom Q.T. Shimmel K. Wolinsky Y. Sloan A.E. De Rose A. Giuliante F. Goodman M. Karlan B.Y. Hagedorn C.H. Eckman J. Harr J. Myers J. Tucker K. Zach L.A. Deyarmin B. Hu H. Kvecher L. Larson C. Mural R.J. Somiari S. Vicha A. Zelinka T. Bennett J. Iacocca M. Rabeno B. Swanson P. Latour M. Lacombe L. Têtu B. Bergeron A. McGraw M. Staugaitis S.M. Chabot J. Hibshoosh H. Sepulveda A. Su T. Wang T. Potapova O. Voronina O. Desjardins L. Mariani O. Roman-Roman S. Sastre X. Stern M-H. Cheng F. Signoretti S. Berchuck A. Bigner D. Lipp E. Marks J. McCall S. McLendon R. Secord A. Sharp A. Behera M. Brat D.J. Chen A. Delman K. Force S. Khuri F. Magliocca K. Maithel S. Olson J.J. Owonikoko T. Pickens A. Ramalingam S. Shin D.M. Sica G. Van Meir E.G. Zhang H. Eijckenboom W. Gillis A. Korpershoek E. Looijenga L. Oosterhuis W. Stoop H. van Kessel K.E. Zwarthoff E.C. Calatozzolo C. Cuppini L. Cuzzubbo S. DiMeco F. Finocchiaro G. Mattei L. Perin A. Pollo B. Chen C. Houck J. Lohavanichbutr P. Hartmann A. Stoehr C. Stoehr R. Taubert H. Wach S. Wullich B. Kycler W. Murawa D. Wiznerowicz M. Chung K. Edenfield W.J. Martin J. Baudin E. Bubley G. Bueno R. De Rienzo A. Richards W.G. Kalkanis S. Mikkelsen T. Noushmehr H. Scarpace L. Girard N. Aymerich M. Campo E. Giné E. Guillermo A.L. Van Bang N. Hanh P.T. Phu B.D. Tang Y. Colman H. Evason K. Dottino P.R. Martignetti J.A. Gabra H. Juhl H. Akeredolu T. Stepa S. Hoon D. Ahn K. Kang K.J. Beuschlein F. Breggia A. Birrer M. Bell D. Borad M. Bryce A.H. Castle E. Chandan V. Cheville J. Copland J.A. Farnell M. Flotte T. Giama N. Ho T. Kendrick M. Kocher J-P. Kopp K. Moser C. Nagorney D. O’Brien D. O’Neill B.P. Patel T. Petersen G. Que F. Rivera M. Roberts L. Smallridge R. Smyrk T. Stanton M. Thompson R.H. Torbenson M. Yang J.D. Zhang L. Brimo F. Ajani J.A. Gonzalez A.M.A. Behrens C. Bondaruk J. Broaddus R. Czerniak B. Esmaeli B. Fujimoto J. Gershenwald J. Guo C. Lazar A.J. Logothetis C. Meric-Bernstam F. Moran C. Ramondetta L. Rice D. Sood A. Tamboli P. Thompson T. Troncoso P. Tsao A. Wistuba I. Carter C. Haydu L. Hersey P. Jakrot V. Kakavand H. Kefford R. Lee K. Long G. Mann G. Quinn M. Saw R. Scolyer R. Shannon K. Spillane A. Stretch J. Synott M. Thompson J. Wilmott J. Al-Ahmadie H. Chan T.A. Ghossein R. Gopalan A. Levine D.A. Reuter V. Singer S. Singh B. Tien N.V. Broudy T. Mirsaidi C. Nair P. Drwiega P. Miller J. Smith J. Zaren H. Park J-W. Hung N.P. Kebebew E. Linehan W.M. Metwalli A.R. Pacak K. Pinto P.A. Schiffman M. Schmidt L.S. Vocke C.D. Wentzensen N. Worrell R. Yang H. Moncrieff M. Goparaju C. Melamed J. Pass H. Botnariuc N. Caraman I. Cernat M. Chemencedji I. Clipca A. Doruc S. Gorincioi G. Mura S. Pirtac M. Stancul I. Tcaciuc D. Albert M. Alexopoulou I. Arnaout A. Bartlett J. Engel J. Gilbert S. Parfitt J. Sekhon H. Thomas G. Rassl D.M. Rintoul R.C. Bifulco C. Tamakawa R. Urba W. Hayward N. Timmers H. Antenucci A. Facciolo F. Grazi G. Marino M. Merola R. de Krijger R. Gimenez-Roqueplo A-P. Piché A. Chevalier S. McKercher G. Birsoy K. Barnett G. Brewer C. Farver C. Naska T. Pennell N.A. Raymond D. Schilero C. Smolenski K. Williams F. Morrison C. Borgia J.A. Liptay M.J. Pool M. Seder C.W. Junker K. Omberg L. Dinkin M. Manikhas G. Alvaro D. Bragazzi M.C. Cardinale V. Carpino G. Gaudio E. Chesla D. Cottingham S. Dubina M. Moiseenko F. Dhanasekaran R. Becker K-F. Janssen K-P. Slotta-Huspenina J. Abdel-Rahman M.H. Aziz D. Bell S. Cebulla C.M. Davis A. Duell R. Elder J.B. Hilty J. Kumar B. Lang J. Lehman N.L. Mandt R. Nguyen P. Pilarski R. Rai K. Schoenfield L. Senecal K. Wakely P. Hansen P. Lechan R. Powers J. Tischler A. Grizzle W.E. Sexton K.C. Kastl A. Henderson J. Porten S. Waldmann J. Fassnacht M. Asa S.L. Schadendorf D. Couce M. Graefen M. Huland H. Sauter G. Schlomm T. Simon R. Tennstedt P. Olabode O. Nelson M. Bathe O. Carroll P.R. Chan J.M. Disaia P. Glenn P. Kelley R.K. Landen C.N. Phillips J. Prados M. Simko J. Smith-McCune K. VandenBerg S. Roggin K. Fehrenbach A. Kendler A. Sifri S. Steele R. Jimeno A. Carey F. Forgie I. Mannelli M. Carney M. Hernandez B. Campos B. Herold-Mende C. Jungk C. Unterberg A. von Deimling A. Bossler A. Galbraith J. Jacobus L. Knudson M. Knutson T. Ma D. Milhem M. Sigmund R. Godwin A.K. Madan R. Rosenthal H.G. Adebamowo C. Adebamowo S.N. Boussioutas A. Beer D. Giordano T. Mes-Masson A-M. Saad F. Bocklage T. Landrum L. Mannel R. Moore K. Moxley K. Postier R. Walker J. Zuna R. Feldman M. Valdivieso F. Dhir R. Luketich J. Pinero E.M.M. Quintero-Aguilo M. Carlotti C.G. Jr Dos Santos J.S. Kemp R. Sankarankuty A. Tirapelli D. Catto J. Agnew K. Swisher E. Creaney J. Robinson B. Shelley C.S. Godwin E.M. Kendall S. Shipman C. Bradford C. Carey T. Haddad A. Moyer J. Peterson L. Prince M. Rozek L. Wolf G. Bowman R. Fong K.M. Yang I. Korst R. Rathmell W.K. Fantacone-Campbell J.L. Hooke J.A. Kovatich A.J. Shriver C.D. DiPersio J. Drake B. Govindan R. Heath S. Ley T. Van Tine B. Westervelt P. Rubin M.A. Lee J.I. Aredes N.D. Mariamidze A. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 2018 173 2 338 354.e15 10.1016/j.cell.2018.03.034 29625051
    [Google Scholar]
  40. Badia-i-Mompel P. Vélez Santiago J. Braunger J. Geiss C. Dimitrov D. Müller-Dott S. Taus P. Dugourd A. Holland C.H. Ramirez Flores R.O. Saez-Rodriguez J. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform. Adv. 2022 2 1 vbac016 10.1093/bioadv/vbac016 36699385
    [Google Scholar]
  41. Newman A.M. Liu C.L. Green M.R. Gentles A.J. Feng W. Xu Y. Hoang C.D. Diehn M. Alizadeh A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015 12 5 453 457 10.1038/nmeth.3337 25822800
    [Google Scholar]
  42. Liu X.D. Kong W. Peterson C.B. McGrail D.J. Hoang A. Zhang X. Lam T. Pilie P.G. Zhu H. Beckermann K.E. Haake S.M. Isgandrova S. Martinez-Moczygemba M. Sahni N. Tannir N.M. Lin S.Y. Rathmell W.K. Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat. Commun. 2020 11 1 2135 10.1038/s41467‑020‑15959‑6 32358509
    [Google Scholar]
  43. Cai W. Su L. Liao L. Liu Z.Z. Langbein L. Dulaimi E. Testa J.R. Uzzo R.G. Zhong Z. Jiang W. Yan Q. Zhang Q. Yang H. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat. Commun. 2019 10 1 5800 10.1038/s41467‑019‑13608‑1 31863007
    [Google Scholar]
  44. Kanu N. Grönroos E. Martinez P. Burrell R.A. Yi Goh X. Bartkova J. Maya-Mendoza A. Mistrík M. Rowan A.J. Patel H. Rabinowitz A. East P. Wilson G. Santos C.R. McGranahan N. Gulati S. Gerlinger M. Birkbak N.J. Joshi T. Alexandrov L.B. Stratton M.R. Powles T. Matthews N. Bates P.A. Stewart A. Szallasi Z. Larkin J. Bartek J. Swanton C. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 2015 34 46 5699 5708 10.1038/onc.2015.24 25728682
    [Google Scholar]
  45. Sato Y. Yoshizato T. Shiraishi Y. Maekawa S. Okuno Y. Kamura T. Shimamura T. Sato-Otsubo A. Nagae G. Suzuki H. Nagata Y. Yoshida K. Kon A. Suzuki Y. Chiba K. Tanaka H. Niida A. Fujimoto A. Tsunoda T. Morikawa T. Maeda D. Kume H. Sugano S. Fukayama M. Aburatani H. Sanada M. Miyano S. Homma Y. Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013 45 8 860 867 10.1038/ng.2699 23797736
    [Google Scholar]
  46. Morris M.R. Ricketts C.J. Gentle D. McRonald F. Carli N. Khalili H. Brown M. Kishida T. Yao M. Banks R.E. Clarke N. Latif F. Maher E.R. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2011 30 12 1390 1401 10.1038/onc.2010.525 21132003
    [Google Scholar]
  47. Cedar H. Bergman Y. Programming of DNA methylation patterns. Annu. Rev. Biochem. 2012 81 1 97 117 10.1146/annurev‑biochem‑052610‑091920 22404632
    [Google Scholar]
  48. Sulewska A. Niklinska W. Kozlowski M. Minarowski L. Naumnik W. Niklinski J. Dabrowska K. Chyczewski L. DNA methylation in states of cell physiology and pathology. Folia Histochem. Cytobiol. 2007 45 3 149 158 17951162
    [Google Scholar]
  49. Wilting R.H. Dannenberg J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updat. 2012 15 1-2 21 38 10.1016/j.drup.2012.01.008 22356866
    [Google Scholar]
  50. Yang X. Gao L. Zhang S. Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief. Bioinform. 2017 18 5 761 773 27436122
    [Google Scholar]
  51. Joosten S.C. Smits K.M. Aarts M.J. Melotte V. Koch A. Tjan-Heijnen V.C. van Engeland M. Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat. Rev. Urol. 2018 15 7 430 451 10.1038/s41585‑018‑0023‑z 29867106
    [Google Scholar]
  52. Clark D.J. Dhanasekaran S.M. Petralia F. Pan J. Song X. Hu Y. da Veiga Leprevost F. Reva B. Lih T.S.M. Chang H.Y. Ma W. Huang C. Ricketts C.J. Chen L. Krek A. Li Y. Rykunov D. Li Q.K. Chen L.S. Ozbek U. Vasaikar S. Wu Y. Yoo S. Chowdhury S. Wyczalkowski M.A. Ji J. Schnaubelt M. Kong A. Sethuraman S. Avtonomov D.M. Ao M. Colaprico A. Cao S. Cho K.C. Kalayci S. Ma S. Liu W. Ruggles K. Calinawan A. Gümüş Z.H. Geiszler D. Kawaler E. Teo G.C. Wen B. Zhang Y. Keegan S. Li K. Chen F. Edwards N. Pierorazio P.M. Chen X.S. Pavlovich C.P. Hakimi A.A. Brominski G. Hsieh J.J. Antczak A. Omelchenko T. Lubinski J. Wiznerowicz M. Linehan W.M. Kinsinger C.R. Thiagarajan M. Boja E.S. Mesri M. Hiltke T. Robles A.I. Rodriguez H. Qian J. Fenyö D. Zhang B. Ding L. Schadt E. Chinnaiyan A.M. Zhang Z. Omenn G.S. Cieslik M. Chan D.W. Nesvizhskii A.I. Wang P. Zhang H. Hashimi A.S. Pico A.R. Karpova A. Charamut A. Paulovich A.G. Perou A.M. Malovannaya A. Marrero-Oliveras A. Agarwal A. Hindenach B. Pruetz B. Kim B-J. Druker B.J. Newton C.J. Birger C. Jones C.D. Tognon C. Mani D.R. Valley D.R. Rohrer D.C. Zhou D.C. Tansil D. Chesla D. Heiman D. Wheeler D. Tan D. Chan D. Demir E. Malc E. Modugno F. Getz G. Hostetter G. Wilson G.D. Hart G.W. Zhu H. Liu H. Culpepper H. Sun H. Zhou H. Day J. Suh J. Huang J. McDermott J. Whiteaker J.R. Tyner J.W. Eschbacher J. Chen J. McGee J. Zhu J. Ketchum K.A. Rodland K.D. Clauser K. Robinson K. Krug K. Hoadley K.A. Um K.S. Elburn K. Holloway K. Wang L-B. Blumenberg L. Hannick L. Qi L. Sokoll L.J. Cornwell M.I. Loriaux M. Domagalski M.J. Gritsenko M.A. Anderson M. Monroe M.E. Ellis M.J. Dyer M. Anurag M. Burke M.C. Borucki M. Gillette M.A. Birrer M.J. Lewis M. Ittmann M.M. Smith M. Vernon M. Chaikin M. Chheda M.G. Khan M. Roche N. Edwards N.J. Vatanian N. Tignor N. Beckmann N. Grady P. Castro P. Piehowski P. McGarvey P.B. Mieczkowski P. Hariharan P. Gao Q. Dhir R. Kothadia R.B. Thangudu R.R. Montgomery R. Jayasinghe R.G. Smith R.D. Edwards R. Zelt R. Bremner R. Liu R. Hong R. Mareedu S. Payne S.H. Cottingham S. Markey S.P. Jewell S.D. Patel S. Satpathy S. Richey S. Davies S.R. Cai S. Boca S.M. Patil S. Sengupta S. Carter S. Gabriel S. Thomas S.N. De Young S. Stein S.E. Carr S.A. Foltz S.M. Hilsenbeck S. Krubit T. Liu T. Skelly T. Westbrook T. Borate U. Velvulou U. Petyuk V.A. Bocik W.E. Chen X. Shi Y. Geffen Y. Lu Y. Wang Y. Maruvka Y. Li Z. Shi Z. Tu Z. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 2019 179 4 964 983.e31 10.1016/j.cell.2019.10.007 31675502
    [Google Scholar]
  53. Hawe J.S. Wilson R. Schmid K.T. Zhou L. Lakshmanan L.N. Lehne B.C. Kühnel B. Scott W.R. Wielscher M. Yew Y.W. Baumbach C. Lee D.P. Marouli E. Bernard M. Pfeiffer L. Matías-García P.R. Autio M.I. Bourgeois S. Herder C. Karhunen V. Meitinger T. Prokisch H. Rathmann W. Roden M. Sebert S. Shin J. Strauch K. Zhang W. Tan W.L.W. Hauck S.M. Merl-Pham J. Grallert H. Barbosa E.G.V. Ahmadi K.R. Ainali C. Barrett A. Bataille V. Bell J.T. Buil A. Dermitzakis E.T. Dimas A.S. Durbin R. Glass D. Grundberg E. Hassanali N. Hedman Å.K. Ingle C. Knowles D. Krestyaninova M. Lindgren C.M. Lowe C.E. McCarthy M.I. Meduri E. di Meglio P. Min J.L. Montgomery S.B. Nestle F.O. Nica A.C. Nisbet J. O’Rahilly S. Parts L. Potter S. Sandling J. Sekowska M. Shin S-Y. Small K.S. Soranzo N. Spector T.D. Surdulescu G. Travers M.E. Tsaprouni L. Tsoka S. Wilk A. Yang T-P. Zondervan K.T. Illig T. Peters A. Paus T. Pausova Z. Deloukas P. Foo R.S.Y. Jarvelin M-R. Kooner J.S. Loh M. Heinig M. Gieger C. Waldenberger M. Chambers J.C. Genetic variation influencing DNA methylation provides insights into molecular mechanisms regulating genomic function. Nat. Genet. 2022 54 1 18 29 10.1038/s41588‑021‑00969‑x 34980917
    [Google Scholar]
  54. Feinberg A.P. Koldobskiy M.A. Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 2016 17 5 284 299 10.1038/nrg.2016.13 26972587
    [Google Scholar]
  55. Nirmaladevi R. Paital B. Jayachandran P. Padma P.R. Nirmaladevi R. Epigenetic alterations in cancer. Front. Biosci. 2020 25 6 1058 1109 10.2741/4847 32114424
    [Google Scholar]
  56. Yang W. Chen H. Ma L. Dong J. Wei M. Xue X. Li Y. Jin Z. Xu W. Ji Z. A comprehensive analysis of the FOX family for predicting kidney renal clear cell carcinoma prognosis and the oncogenic role of FOXG1. Aging 2022 14 24 10107 10124 10.18632/aging.204448 36585925
    [Google Scholar]
  57. Wang X. Lamberti G. Di Federico A. Alessi J. Ferrara R. Sholl M.L. Awad M.M. Vokes N. Ricciuti B. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: Challenges and opportunities. Ann. Oncol. 2024 35 6 508 522 10.1016/j.annonc.2024.03.007 38537779
    [Google Scholar]
  58. Mihaila R.I. Gheorghe A.S. Zob D.L. Stanculeanu D.L. The importance of predictive biomarkers and their correlation with the response to immunotherapy in solid tumors—impact on clinical practice. Biomedicines 2024 12 9 2146 10.3390/biomedicines12092146 39335659
    [Google Scholar]
  59. Ahmed J. Das B. Shin S. Chen A. Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies. Cancers (Basel) 2023 15 24 5841 10.3390/cancers15245841 38136385
    [Google Scholar]
  60. Anagnostou V. Bardelli A. Chan T.A. Turajlic S. The status of tumor mutational burden and immunotherapy. Nat. Cancer 2022 3 6 652 656 10.1038/s43018‑022‑00382‑1 35764740
    [Google Scholar]
  61. Pavelescu L.A. Enache R.M. Roşu O.A. Profir M. Creţoiu S.M. Gaspar B.S. Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in malignant solid tumors. Int. J. Mol. Sci. 2024 25 17 9659 10.3390/ijms25179659 39273605
    [Google Scholar]
  62. Xie Y. Sahin M. Sinha S. Wang Y. Nargund A.M. Lyu Y. Han S. Dong Y. Hsieh J.J. Leslie C.S. Cheng E.H. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat. Cancer 2022 3 2 188 202 10.1038/s43018‑021‑00316‑3 35115713
    [Google Scholar]
  63. Wang T. Wagner R.T. Hlady R.A. Pan X. Zhao X. Kim S. Wang L. Lee J.H. Luo H. Castle E.P. Lake D.F. Ho T.H. Robertson K.D. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF -β-independent manner. Mol. Oncol. 2024 18 1 44 61 10.1002/1878‑0261.13487 37418588
    [Google Scholar]
  64. Wang J. Liu L. Qu Y. Xi W. Xia Y. Bai Q. Xiong Y. Long Q. Xu J. Guo J. Prognostic value of SETD2 expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. J. Urol. 2016 196 5 1363 1370 10.1016/j.juro.2016.06.010 27288695
    [Google Scholar]
  65. Klein C.B. Costa M. DNA methylation, heterochromatin and epigenetic carcinogens. Mutat. Res. Rev. Mutat. Res. 1997 386 2 163 180 10.1016/S1383‑5742(96)00052‑X 9113117
    [Google Scholar]
  66. Kundu T.K. Rao M.R.S. CpG islands in chromatin organization and gene expression. J. Biochem. 1999 125 2 217 222 10.1093/oxfordjournals.jbchem.a022276 9990116
    [Google Scholar]
  67. Smith J. Sen S. Weeks R.J. Eccles M.R. Chatterjee A. Promoter DNA hypermethylation and paradoxical gene activation. Trends Cancer 2020 6 5 392 406 10.1016/j.trecan.2020.02.007 32348735
    [Google Scholar]
  68. Kalsbeek D. Golsteyn R. G2/M-phase checkpoint adaptation and micronuclei formation as mechanisms that contribute to genomic instability in human cells. Int. J. Mol. Sci. 2017 18 11 2344 10.3390/ijms18112344 29113112
    [Google Scholar]
  69. Ren B. Cam H. Takahashi Y. Volkert T. Terragni J. Young R.A. Dynlacht B.D. E2F integrates cell cycle progression with DNA repair, replication, and G 2 /M checkpoints. Genes Dev. 2002 16 2 245 256 10.1101/gad.949802 11799067
    [Google Scholar]
  70. Poprach A. Lakomý R. Büchler T. Immunotherapy of renal cell carcinoma. Klin. Onkol. 2017 30 Suppl. 3 3S55 , 3S61 10.14735/amko20173S55 29239194
    [Google Scholar]
  71. Bahadoram S. Davoodi M. Hassanzadeh S. Bahadoram M. Barahman M. Mafakher L. Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatment. G. Ital. Nefrol. 2022 39 3 2022-vol3 35819037
    [Google Scholar]
  72. Kapoor A. First-line treatment options in metastatic renal cell cancer. Can. Urol. Assoc. J. 2016 10 S17 S236 S238 10.5489/cuaj.4307
    [Google Scholar]
  73. Sánchez-Gastaldo A. Kempf E. González del Alba A. Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat. Rev. 2017 60 77 89 10.1016/j.ctrv.2017.08.010 28898679
    [Google Scholar]
  74. Buti S. Bersanelli M. Sikokis A. Maines F. Facchinetti F. Bria E. Ardizzoni A. Tortora G. Massari F. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 2013 24 6 535 554 10.1097/CAD.0b013e3283609ec1 23552469
    [Google Scholar]
  75. Acharya N. Singh K.P. Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma. WIREs Mech. Dis. 2022 14 6 e1575 10.1002/wsbm.1575 35861307
    [Google Scholar]
  76. Schey C. Meier G. Pan J. Metastatic renal cell cancer: An analysis of reimbursement decisions. Adv. Ther. 2019 36 6 1266 1278 10.1007/s12325‑019‑00947‑0 30953332
    [Google Scholar]
  77. Goldsamt A. Damayanti N.P. De Nigris F. Pili R. Epigenetic dysregulation in advanced kidney cancer. Cancer J. 2020 26 5 399 406 10.1097/PPO.0000000000000479 32947308
    [Google Scholar]
  78. Wang Y. Tong C. Dai H. Wu Z. Han X. Guo Y. Chen D. Wei J. Ti D. Liu Z. Mei Q. Li X. Dong L. Nie J. Zhang Y. Han W. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat. Commun. 2021 12 1 409 10.1038/s41467‑020‑20696‑x 33462245
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673342146250217105350
Loading
Prognostic Role of Global DNA Methylation in Renal Cancer Reveals Decitabine Treatment Benefit
Bentham Science Publishers ; https://doi.org/10.2174/0109298673342146250217105350
/content/journals/cmc/10.2174/0109298673342146250217105350
/content/journals/cmc/10.2174/0109298673342146250217105350
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: global DNA methylation ; decitabine ; Renal cancer ; prognosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test